Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) Equity Average (2016 - 2026)

Pharma-Bio Serv filings provide 14 years of Equity Average readings, the most recent being $11.1 million for Q1 2026.

  • On a quarterly basis, Equity Average fell 13.84% to $11.1 million in Q1 2026 year-over-year; TTM through Jan 2026 was $11.1 million, a 13.84% decrease, with the full-year FY2025 number at $12.8 million, down 14.12% from a year prior.
  • Equity Average hit $11.1 million in Q1 2026 for Pharma-Bio Serv, down from $11.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $18.2 million in Q1 2022 to a low of $11.1 million in Q1 2026.
  • Median Equity Average over the past 5 years was $15.1 million (2024), compared with a mean of $14.7 million.
  • Biggest five-year swings in Equity Average: dropped 29.4% in 2022 and later dropped 0.57% in 2023.
  • Pharma-Bio Serv's Equity Average stood at $16.4 million in 2022, then dropped by 1.2% to $16.2 million in 2023, then fell by 15.2% to $13.7 million in 2024, then decreased by 13.0% to $11.9 million in 2025, then fell by 7.08% to $11.1 million in 2026.
  • The last three reported values for Equity Average were $11.1 million (Q1 2026), $11.9 million (Q4 2025), and $12.0 million (Q3 2025) per Business Quant data.